Three additional generic manufacturing partners join efforts to increase access to generic hepatitis C treatment glecaprevir/pibrentasvir
The International Diabetes Federation and the Medicines Patent Pool welcome the inclusion of SGLT2 inhibitors to the WHO Essential Medicines List
WHO Essential Medicines Committee calls for licensing of key medicines to MPP to support affordable access in low- and middle-income countries
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries.
Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups and other stakeholders, to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 11 patent holders for thirteen HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment and a licence for long-acting technologies.
In 2020, MPP’s mandate was temporarily expanded to include COVID-19 treatments. In 2021 it was expanded further to include the licensing of technology with an initial focus on COVID-19 vaccines and pandemic preparedness. MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC).
"The Medicines Patent Pool was established as a landmark initiative to expand access to treatments for priority diseases. Over the last decade, MPP has become a strong partner in global health, working to facilitate access to HIV and hepatitis C medicines in low- and middle-income countries through voluntary licensing and patent pooling. With its impressive track record, MPP has a critical role to play in making affordable versions of patented essential medicines and technologies available to those who need it the most, including for COVID-19."Dr Tedros Adhanom Ghebreyesus, Director-General, World Health Organization
"The creation fo the Medicines Patent Pool by Unitaid ten years ago enabled the production of generics that treat tens of millions of people around the world. This led to important successes such as an annual treatment for HIV/AIDS for less than USD 70 in Africa, instead of USD 10,000 in Europe. Today, maybe more than ever, we need MPP’s model to help pharmaceutical companies license their rights on a voluntary basis and continue to save lives."Marisol Touraine, Chair of the Executive Board of Unitaid
"As the Medicines Patent Pool celebrates its ten-year anniversary, we are proud to support MPP’s effort to speed up access to essential medicines in low- and middle-income countries. MPP’s voluntary licence mechanism is very much needed, especially in times of the COVID-19 pandemic, as it promotes a collaborative vision of ensuring rapid access of quality-assured affordable essential medicines to people living in low- and middle-income countries while acknowledging the need to fund innovation."Alexander Schulze, Head of the Division Global Programme Health, Federal Department of Foreign Affairs, Swiss Agency for Development and Cooperation
MPP in Numbers
patent holders with MPP signed agreements
generic manufacturers and product developers have sublicences from MPP
countries have benefitted from access to MPP-licensed products
ongoing pharmaceutical development projects
Billion dollars saved by the international community, from January 2012 to December 2020
Billion doses of treatment supplied from January 2012 to December 2020
Million patient-years of treatment through MPP’s generic partners, from January 2012 to December 2020
For Everyone Everywhere
Discover where we helped and what we have achieved
Patent and licensing status: last updated on 11 May 2021. Disclaimer | Product availability data from MPP sublicensees: last updated in October 2021 (data as of 30 June 2021) | Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions
How access to antiretrovirals is building the future
💻>MPP-@WHO #WHS2021 panel discussion will explore key opportunities & challenges for making #EssentialMedicines for #NCDs accessible in #LMICs. 🎙️Joining us👉@Cancer_ZA @IFPMA @IntDiabetesFed @UNITAID @SwissDevCoop @noradno ⏰26 October | 9.00-10.30 CET 👉https://t.co/4FSI7T8zJ3 https://t.co/y3eYWlvCQi
Cape Heart Institute | Global Medicine @CHI_UCT
#WHS2021: panel discussion on access to #EssentialMedicines for #NCDs in #LMICs. Our very own Prof. Karen Sliwa will be giving a talk: Access to cardiometabolic, hypertension and diabetes treatments. #DefeatNCDs #Access2Meds Read more: https://t.co/v00duBU6Al https://t.co/ottBCFTVpZ
📢💻> Join us live at #WHS2021: we’re co-hosting a panel discussion with @WHO on access to #EssentialMedicines for #NCDs in #LMICs ⏰26 October 2021 | 9.00-10.30 CET 👉Stream live for free: https://t.co/4FSI7T8zJ3 #DefeatNCDs #Access2Meds @WorldHealthSmt https://t.co/rY2aWncRkO
Today, to mark the launch of the 2021 Global Tuberculosis Report, the @WHO is organizing a symposium with interventions from @UNITAID. The event will showcase the work undertaken to ramp up the TB response, especially in the context of #COVID19. Details👇 https://t.co/NXoQ83RPLv https://t.co/xrgvJ5Sgpv